Evidence map›Paper›PMID 26437267›Full record

ArticleDepression and anxiety2015

INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALS.

Bret R Rutherford, Veronika S Bailey, Franklin R Schneier, Emily Pott, Patrick J Brown, Steven P Roose

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Depression and anxiety, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Short-term open-label chamomile (Matricaria chamomilla L.) therapy of moderate to severe generalized anxiety disorder.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2016
    Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bret R RutherfordColumbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, New York.
Veronika S BaileyNew York State Psychiatric Institute, New York, New York.
Franklin R SchneierColumbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, New York.
Emily PottNew York State Psychiatric Institute, New York, New York.
Patrick J BrownColumbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, New York.
Steven P RooseColumbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, New York.

Funding

The Phenomenology and Antidepressant Treatment of Depressed, Frail Older AdultsK23MH099097 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI BROWN, PATRICK J · 2013 to 2017
$850k
NIMH NIH HHS K23 MH099097
6 · The paper itself

Abstract

objectiveThe influence of study design variables and publication year on response to medication and placebo was investigated in clinical trials for social anxiety disorder (SAD), generalized anxiety disorder (GAD), and panic disorder (PD).

methodHierarchical linear modeling determined whether publication year, treatment assignment (medication vs. placebo), study type (placebo-controlled or active comparator), study duration, and the number of study visits affected the mean change associated with medication and placebo.

resultsIn the 66 trials examined, the change associated with both medication and placebo increased over time (t = 4.23, df = 39, P < .001), but average drug-placebo differences decreased over time (t = -2.04, df = 46, P = .047). More severe baseline illness was associated with greater drug-placebo differences for serotonin norepinephrine reuptake inhibitors (SNRIs, t = 3.46, df = 106, P = .001) and selective serotonin reuptake inhibitors (SSRI, t = 10.37, df = 106, P < .001). Improvement with medication was significantly greater in active-comparator studies compared to placebo-controlled trials (t = 3.41, df = 39, P = .002). A greater number of study visits was associated with greater symptom improvement in PD trials relative to SAD (t = 2.83, df = 39, P = .008) and GAD (t = 2.16, df = 39, P = .037).

conclusionsPlacebo response is substantial in SAD, GAD, and PD trials, and its rise over time has been associated with diminished drug-placebo differences. Study design features that influence treatment response in anxiety disorder trials include patient expectancy, frequency of follow-up visits, and baseline illness severity.

Indexed as

AdultAnxiety DisordersClinical Trials as TopicFemaleHumansMalePanic DisorderRandomized Controlled Trials as TopicResearch DesignSelective Serotonin Reuptake InhibitorsSelective Serotonin Reuptake Inhibitorsantidepressantsanxiety/anxiety disorderclinical trialspharmacotherapytreatment

Identifiers

PMID26437267
PMCPMC4922308

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.